4582.T) announced today that it has achieved its first patient enrollment (FPI) in a">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from SymBio Pharmaceuticals Limited was processed by Pulse News Wire on March 17, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

SymBio Pharmaceuticals: Completes First Patient Enrollment in Global Phase III Trial for AdV Infections Post-Hematopoietic Stem Cell Transplantation

TOKYO, Mar 17 (Pulse News Wire) – SymBio Pharmaceuticals Limited (4582.T) announced today that it has achieved its first patient enrollment (FPI) in a global Phase III clinical trial for Adenovirus (A

View all 4582.T disclosures →

Share this disclosure: Share on X Share on LinkedIn